Two Cases of Bipolar Disorder Successfully Stabilized for Five Years with a Low Dose of Risperidone and Lithium

Two patients with bipolar I disorder were successfully treated with a combination of risperidone and lithium in their acute manic states and maintenance periods. Although lithium monotherapy alone could not prevent relapse in these patients, the addition of a low dose of risperidone was well tolerated and effective for preventing recurrence over the long term. Plasma levels of HVA and MHPG were found to be elevated during the manic episodes and gradually decreased after the risperidone treatment. These results indicate that a low dose of risperidone to the lithium regimen was an effective and well tolerated means for treatment in the acute manic state and the later maintenance period in parallel with decreasing plasma levels of HVA and MHPG.

References

• 1 Americal Psychiatric Association. Practice Guideline for the Treatment of Patients with Bipolar Disorder (revision).  Am J Psychiatry. 2002;  159 ((Suppl 4)) 1-50
• 2 Bowden CL, Myers JE, Grossman F, Xie Y. Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder.  J Clin Psychiatry. 2004;  65 707-714
• 3 Lambert M, Conus P, Schimmelmann BG, Eide P, Ward J, Yuen H, Schacht M, Edwards J, Naber D, McGorry PD. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study.  Pharmacopsychiatry. 2005;  38 206-213
• 4 Mazure CM, Bowers MB. Pretreatment plasma HVA predicts neuroleptic response in manic psychosis.  J Affect Disord. 1998;  48 83-86
• 5 Miller DS, Yatham LN, Lam RW. Comparative efficacy of typical and atypical antipsychotics add-on therapy to mood stabilizers in the treatment of acute mania.  J Clin Psychiatry. 2001;  62 975-980
• 6 Narendran R, Young CM, Valenti AM, Pristach CA, Pato MT, Grace JJ. Olanzapine therapy in treatment -resistant psychotic mood disorders: a long-term follow-up study.  J Clin Psychiatry. 2001;  62 509-516
• 7 Rybakowski JK, Suwalska A, Skibinska M, Szczepankiewicz A, Leszynska-Rodziewicz A, Permoda A, Czerski PM, Hauser J. Prolylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene.  Pharmacopsychiatry. 2005;  38 166-170
• 8 Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.  Am J Psychiatry. 2002;  159 1146-1154
• 9 Swann AC, Secunda S, Davis JM, Robins E, Hanin I, Koslow SH, Maas JW. CSF monoamine metabolites in mania.  Am J Psychiatry. 1983;  140 396-400
• 10 Vestergaard P, Sorensen T, Hoppe E, Rafaelsen OJ, Yates CM, Nicolou N. Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders.  Acta Psychitr Scand. 1978;  58 88-96
• 11 Yoshimura R, Nakamura J, Shinkai K, Goto M, Yamada Y, Kaji K, Kakihara S, Ueda N, Kohara K, Ninomiya H, Egami H, Maeda H. An open study of risperidone liquid in the acute phase of schizophrenia.  Hum Psychopharmacol. 2005;  20 243-248

Correspondence